Drug Interactions in Space: a Cause for Concern?
- 31 May 2019
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 36 (8), 114
- https://doi.org/10.1007/s11095-019-2649-9
Abstract
Crewmembers aboard the International Space Station (ISS) have free access to an increasing number of medications within medical kits. The aim of the current study was to assess the number, severity and reliability of potential drug-drug interactions (DDIs) involving those medications.This publication has 28 references indexed in Scilit:
- Similarity-based modeling in large-scale prediction of drug-drug interactionsNature Protocols, 2014
- Drug interaction alert override rates in the Meaningful Use eraApplied Clinical Informatics, 2014
- Can I take a space flight? Considerations for doctorsBMJ, 2012
- Provider and pharmacist responses to warfarin drug-drug interaction alerts: a study of healthcare downstream of CPOE alertsJournal of the American Medical Informatics Association, 2011
- Critical issues associated with drug–drug interactions: Highlights of a multistakeholder conferenceAmerican Journal of Health-System Pharmacy, 2011
- Comparison of Critical Drug–Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference CompendiaClinical Pharmacology & Therapeutics, 2009
- Unintended consequences of reducing QT-alert overload in a computerized physician order entry systemEuropean Journal of Clinical Pharmacology, 2009
- Physiological, Pharmacokinetic, and Pharmacodynamic Changes in SpaceThe Journal of Clinical Pharmacology, 2004
- Effect of short- and long-duration spaceflight on QTc intervals in healthy astronautsThe American Journal of Cardiology, 2003
- Chapter 4 Pharmacology in Space: PharmacotherapyAdvances in space biology and medicine, 1997